PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.
-0.21
Negative OCF/share while Drug Manufacturers - Specialty & Generic median is -0.03. Seth Klarman would examine if a turnaround is realistic.
-0.24
Negative FCF/share while Drug Manufacturers - Specialty & Generic median is -0.07. Seth Klarman would question if the business is too capex-heavy.
-17.50%
Negative ratio while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would examine if negative OCF or unusual accounting drives this figure.
2.69
Ratio above 1.5x Drug Manufacturers - Specialty & Generic median of 0.56. Joel Greenblatt would see if robust OCF is a recurring trait.
-55.48%
Negative ratio while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would suspect deeper operational issues or near-zero revenue.